Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lucien Parrillo

Interventional Pain Medicine Lakeland, FL Medical Doctor

NPI 1477752186 CMS profile 66410

4310 S Florida Ave, Lakeland, FL 33813

Open in the dashboard

General payments

$16,646

393 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lucien Parrillo of Lakeland, FL is reported in the CMS Open Payments database as having received $16,646 across 393 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,716 73
2024 General $2,038 68
2023 General $5,073 65
2022 General $1,850 78
2021 General $936 44
2020 General $1,907 39
2019 General $1,127 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lucien Parrillo
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Lucien Parrillo were reported at $3,716. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Lucien Parrillo Interventional Pain Medicine median Middle half National median
2019 $1,127 $684 $216–$2,079 $163
2020 $1,907 $382 $122–$1,109 $114
2021 $936 $552 $167–$1,554 $132
2022 $1,850 $605 $187–$1,924 $149
2023 $5,073 $671 $195–$1,915 $160
2024 $2,038 $684 $206–$1,837 $164
2025 $3,716 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $7,795 137 payments
  2. Nutech Spine, Inc. $2,500 1 payment
  3. Abbott Laboratories $1,429 45 payments
  4. Foundation Fusion Solutions, LLC $665 9 payments
  5. Amgen Inc. $645 21 payments
  6. Curonix LLC $558 23 payments
  7. AbbVie, Inc. $380 19 payments
  8. Painteq LLC $317 9 payments
  9. Allergan Inc. $237 18 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $226 13 payments
  11. Other $1,894 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,737 372 payments
  2. Travel and Lodging $3,238 17 payments
  3. Consulting Fee $2,500 1 payment
  4. Education $171 3 payments
Products named General payments · program years 2019–2025
  1. SiFix $2,500 1 payment
  2. SUPERION $1,375 12 payments
  3. Superion Indirect Decompression System $1,198 29 payments
  4. Intracept $1,013 4 payments
  5. Proclaim Family of SCS IPGs $769 8 payments
  6. WaveWriter Alpha Prime 16 $769 20 payments
  7. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $548 22 payments
  8. Intracept RF Probe $501 8 payments
  9. EVENITY $460 18 payments
  10. Qutenza $370 18 payments
  11. Other $5,483 288 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

6,790

Median for Interventional Pain Management: 1,220

Drug cost

$401,311

Median for Interventional Pain Management: $39,344

Branded share of claims

49.2%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Percocet Oxycodone Hcl/Acetaminophen Brand 22 $85,790
Xtampza Er Oxycodone Myristate Brand 83 $54,709
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,340 $54,008
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,329 $33,952
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 163 $26,699
Belbuca Buprenorphine Hcl Brand 27 $26,383
Nucynta Er Tapentadol Hcl Brand 12 $19,137
Buprenorphine Generic 68 $16,323
Oxycontin Oxycodone Hcl Brand 13 $14,039
Pregabalin Generic 606 $12,442

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$424,965

Of which drugs: $38,923

Medicare patients

475

Average age 75

Services billed

19,821

282 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 46%
Diabetes 36%
Ischemic heart disease 35%
Depression 35%
Osteoporosis 27%
COPD 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 45 154 $851
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 134 1,763 $508
Injection, methylprednisolone acetate, 1 mg J1010 Office 54 3,975 $405
Injection, methylprednisolone acetate, 40 mg J1030 Office 51 55 $273
Injection, ketorolac tromethamine, per 15 mg J1885 Office 40 210 $111
Injection, methylprednisolone acetate, 80 mg J1040 Office 12 13 $84

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $88
$88 — —
BOTOX
  • AbbVie, Inc. $56
$56 — —
EVENITY
  • Amgen Inc. $56
$56 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $50
$50 27 —
Prolia
  • Amgen Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

393 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record